We are live on ! Find out more
PI

Pennant Investors Portfolio holdings

AUM $361M
1-Year Est. Return 134.26%
This Fund
S&P 500
This Quarter Est. Return
+19.01%
1 Year Est. Return
+134.26%
3 Year Est. Return
+359.01%
5 Year Est. Return
+289.76%
10 Year Est. Return
–
AUM
$404M
AUM Growth
-$54.4M
Cap. Flow
-$97M
Cap. Flow %
-24.04%
Top 10 Hldgs %
88.07%
Holding
46
New
2
Increased
1
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
ENOV icon
Enovis
ENOV
+$23.9M
2
AR icon
Antero Resources
AR
+$5.31M

Top Sells

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$25.2M
2
AMZN icon
Amazon
AMZN
+$8.68M
3
MSFT icon
Microsoft
MSFT
+$6.88M
4
TVTX icon
Travere Therapeutics
TVTX
+$502K

Sector Composition

Rank Sector Weight
1 Technology 20.64%
2 Consumer Discretionary 18.48%
3 Communication Services 15.04%
4 Industrials 12.92%
5 Healthcare 10.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
26
Agios Pharmaceuticals
AGIO
$1.93B
$442K 0.11%
15,100
– –
GETR
27
DELISTED
Getaround, Inc.
GETR
$414K 0.1%
1,348,153
– –
ZYME icon
28
Zymeworks
ZYME
$1.67B
$407K 0.1%
38,700
– –
CHRS icon
29
Coherus Oncology
CHRS
$196M
$402K 0.1%
168,100
– –
CMPX icon
30
Compass Therapeutics
CMPX
$387M
$394K 0.1%
199,000
– –
RLAY icon
31
Relay Therapeutics
RLAY
$4.33B
$352K 0.09%
42,400
– –
ERAS icon
32
Erasca
ERAS
$6.39B
$342K 0.08%
166,200
– –
SAGE
33
DELISTED
Sage Therapeutics
SAGE
$328K 0.08%
17,500
– –
NVAX icon
34
Novavax
NVAX
$1.31B
$288K 0.07%
60,300
– –
AGEN
35
Agenus
AGEN
$290M
$272K 0.07%
23,480
– –
QURE icon
36
uniQure
QURE
$3.22B
$252K 0.06%
48,500
– –
REPL icon
37
Replimune Group
REPL
$1.01B
$249K 0.06%
30,500
– –
BTAI icon
38
BioXcel Therapeutics
BTAI
$27.8M
$237K 0.06%
5,244
– –
ALLK
39
DELISTED
Allakos
ALLK
$234K 0.06%
186,100
– –
MCRB icon
40
Seres Therapeutics
MCRB
$48.9M
$226K 0.06%
14,615
– –
KLRS
41
Kalaris Therapeutics
KLRS
$96.8M
$163K 0.04%
9,378
– –
MIMO
42
DELISTED
Airspan Networks Holdings Inc
MIMO
$118K 0.03%
1,047,473
– –
BLUE
43
DELISTED
bluebird bio
BLUE
$112K 0.03%
4,370
– –
GRABW icon
44
Grab Holdings Warrant
GRABW
$738K
$16.2K ﹤0.01%
80,000
– –
TVTX icon
45
Travere Therapeutics
TVTX
$5.78B
– –
-55,800
Closed -$502K
1
2

Similar funds

BCC
Bridge City Capital Lake Oswego, Oregon $361M AUM 38.29% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return

Pennant Investors's Q1 2024 Portfolio in Review

As of Q1 2024, Pennant Investors held 46 positions worth $404M, down 12% from $458M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Pennant Investors withdrew a net $97M in Q1 2024, closing 1 position and reducing 4 holdings. Its most notable exit was Travere Therapeutics, an estimated $502K position sold in full.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Communication Services.

Against the trend, Pennant Investors opened a new position in Enovis worth $25M.

  • Pennant Investors's largest Q1 2024 buy was Enovis: 400,000 shares worth $25M.
  • Pennant Investors added most to Antero Resources in Q1 2024, an estimated $5.31M increase.
  • Pennant Investors's biggest Q1 2024 reduction was Alphabet (Google) Class A, cutting an estimated $25.2M.
  • Pennant Investors fully exited Travere Therapeutics in Q1 2024, selling an estimated $502K.
  • Pennant Investors's ten largest holdings make up 88% of its $404M portfolio in Q1 2024.
  • Pennant Investors opened 2 new positions and closed 1 in Q1 2024.
  • Pennant Investors's portfolio value fell 12% quarter-over-quarter to $404M.

Based on Pennant Investors's 13F filing for Q1 2024, filed 15 May 2024.